進行性腎細胞癌に対するインターフェロン-αとOK-432の併用療法

概要

論文の詳細を見る
12例中,4例に有効であり,肺転移11例中4例,骨転移5例中2例に腫瘍の縮小がみられた。HLBI単独療法が無効であった4例と効果が一時的であった1例中2例にも腫瘍の縮小が認められたA total of 12 patients with advanced renal cell carcinoma received interferon alpha (3 million units intramuscularly 6 times weekly) and OK-432 (5 KE (Klinische Einheit) intramuscularly twice weekly). Metastatic lesions appeared before operation in six patients and after operation in six patients. Among them 5 patients had received interferon therapy and this combination therapy was started after the judgment of progressive disease for interferon therapy. Eleven pulmonary and 5 bone metastases were evaluable. The median duration of the combination therapy was 89.3 weeks. There were 4 partial responses and no complete responses among the 12 patients, giving a response rate of 33.3%. The median duration of response was 25 months, with a range of 6 to 54 months. Responses were seen predominantly in patients in whom metastases appeared after operation (3 of 4 responders). However, regarding the individual organs, two complete and 2 partial responses were observed among 11 pulmonary metastases and 2 partial responses among 5 bone metastases. The survival period after discovery of the metastasis was 10 to 67 months and the 5-year survival rate was 70.5%. Almost all patients had fever and induration at the injection site. Other side effects included leukopenia, anorexia, and depression. This combination therapy is thought to be effective against bone or other organs metastasis resistant to interferon alone.

著者

名出頼男
公立福生病院

進行性腎細胞癌に対するインターフェロン-αとOK-432の併用療法

スポンサーリンク

概要

著者

関連論文

スポンサーリンク